{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:53:53Z","timestamp":1790790833460,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012693.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000}}],"reference-count":136,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012693.pub3","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T12:01:39Z","timestamp":1704369699000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)"],"prefix":"10.1002","volume":"2024","author":[{"given":"Olina","family":"Ngwenya","sequence":"additional","affiliation":[{"name":"Centre for Biostatistics, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre (MAHSC); University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah F","family":"Lensen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology; University of Melbourne; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Vail","sequence":"additional","affiliation":[{"name":"Centre for Biostatistics; University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Willem J","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology; Monash University; Clayton Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J","family":"Broekmans","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Reproductive Medicine; University Medical Centre; Utrecht, Heidelberglaan Netherlands"},{"name":"Centre For Fertility Care; Dijklander Hospital; Waterlandlaan, Purmerend Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Centre for Biostatistics, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre (MAHSC); University of Manchester; Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD012693.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rbmo.2017.01.012","article-title":"A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF\/ICSI cycles","volume":"34","author":"Allegra","year":"2017","journal-title":"Reproductive Biomedicine Online"},{"issue":"6","key":"10.1002\/14651858.CD012693.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.fertnstert.2014.08.013","article-title":"Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization\/ intracytoplasmic sperm injection","volume":"102","author":"Arce","year":"2014","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejogrb.2016.05.027","article-title":"A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response","volume":"203","author":"Bastu","year":"2016","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0004|cit4","first-page":"21","article-title":"Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial","volume":"10","author":"Cavagna","year":"2006","journal-title":"Jornal Brasileiro de Reproducao Assistida"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0015-0282(00)01643-5","article-title":"A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-\u03b2) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles","volume":"75","author":"Harrison","year":"2001","journal-title":"Fertility and Sterility"},{"issue":"10","key":"10.1002\/14651858.CD012693.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1023\/A:1020358419073","article-title":"A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF\/ICSI","volume":"19","author":"Hoomans","year":"2002","journal-title":"Journal of Assisted Reproduction and Genetics"},{"issue":"6","key":"10.1002\/14651858.CD012693.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.fertnstert.2020.10.059","article-title":"Randomized, assessor-blind, antimullerian hormone\u2013stratified, dose-response trial in Japanese in vitro fertilization\/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta","volume":"115","author":"Ishihara","year":"2021","journal-title":"Fertility and Sterility"},{"issue":"5","key":"10.1002\/14651858.CD012693.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.rbmo.2021.01.023","article-title":"Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF\/ICSI patients: a randomized controlled trial","volume":"42","author":"Ishihara","year":"2021","journal-title":"Reproductive BioMedicine Online"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1471-0528.2010.02545.x","article-title":"A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count","volume":"117","author":"Jayaprakasan","year":"2010","journal-title":"British Journal of Obstetrics and Gynaecology"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/humrep\/deh663","article-title":"Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial","volume":"20","author":"Klinkert","year":"2005","journal-title":"Human Reproduction"},{"issue":"4","key":"10.1002\/14651858.CD012693.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.rbmo.2013.07.008","article-title":"Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH","volume":"27","author":"Lan","year":"2013","journal-title":"Reproductive BioMedicine Online"},{"issue":"6","key":"10.1002\/14651858.CD012693.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.fertnstert.2015.08.014","article-title":"450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial","volume":"104","author":"Lefebvre","year":"2015","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Liu X Wen W Tao W Li T Na L Ting S Individualized versus standard FSH dosing in predicted poor responders: an RCT Human Reproduction 2021 36 Suppl 1 https:\/\/doi.org\/10.1093\/humrep\/deab127.055","DOI":"10.1093\/humrep\/deab127.055"},{"issue":"8","key":"10.1002\/14651858.CD012693.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/humrep\/deac113","article-title":"Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial","volume":"37","author":"Liu","year":"2022","journal-title":"Human Reproduction"},{"issue":"4","key":"10.1002\/14651858.CD012693.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/humrep\/dex012","article-title":"The addition of anti-M\u00fcllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response\u2014a randomized, controlled trial","volume":"32","author":"Nilsson","year":"2017","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","article-title":"Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial","volume":"107","author":"Nyboe Andersen","year":"2017","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.rbmo.2014.11.013","article-title":"Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa","volume":"30","author":"Olivennes","year":"2015","journal-title":"Reproductive BioMedicine Online"},{"issue":"12","key":"10.1002\/14651858.CD012693.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/humrep\/dex319","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 2: the predicted hyper responder","volume":"32","author":"Oudshoorn","year":"2017","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/humrep\/deh044","article-title":"A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction","volume":"19","author":"Out","year":"2004","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0020|cit20","first-page":"1","article-title":"A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF","volume":"1","author":"Petersen","year":"2019","journal-title":"Human Reproduction Open"},{"issue":"11","key":"10.1002\/14651858.CD012693.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/humrep\/deg472","article-title":"A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU\/day in 'standard' patients undergoing IVF\/ICSI treatment","volume":"18","author":"Popovic-Todorovic","year":"2003","journal-title":"Human Reproduction"},{"issue":"9","key":"10.1002\/14651858.CD012693.pub3-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1093\/humrep\/deab155","article-title":"A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients","volume":"39","author":"Qiao","year":"2021","journal-title":"Human Reproduction"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1142\/S2661318221500146","article-title":"Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial)","volume":"3","author":"Shyamsunder","year":"2021","journal-title":"Fertility and Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10815-005-1497-1","article-title":"A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment","volume":"22","author":"Tan","year":"2005","journal-title":"Journal of Assisted Reproduction and Genetics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012693.pub3-BIB0025|cit25","first-page":"i170","article-title":"A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF\/ICSI treatment","volume":"25","author":"Tasker","year":"2010","journal-title":"Human Reproduction"},{"issue":"12","key":"10.1002\/14651858.CD012693.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/humrep\/dex318","article-title":"Individualized versus standard FSH dosing in women starting IVF\/ICSI: an RCT. Part 1: the predicted poor responder","volume":"32","author":"Van Tilborg","year":"2017","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0015-0282(02)04583-1","article-title":"A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment","volume":"79","author":"Yong","year":"2003","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejogrb.2017.05.005","article-title":"Local endometrial injury in women with failed IVF undergoing a repeat cycle: A randomized controlled trial","volume":"214","author":"Aleyamma","year":"2017","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.fertnstert.2009.03.027","article-title":"What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?","volume":"94","author":"Berkkanoglu","year":"2010","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0030|cit30","first-page":"7","article-title":"A multicentre, prospective, randomised study to compare low dose protocol versus conventional administration of Rh-FSH (GONAL-F) in normo-responders undergoing ART","volume":"1","author":"Camier","year":"1999","journal-title":"Congress of Controversies in Obstestrics, Gynaecology and Infertility"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0031|cit31","first-page":"66","article-title":"A prospective and randomized trial comparing 225IU and 300 IU follitropin-alpha; in a fixed-dose regimen for controlled ovarian stimulation","volume":"24","author":"Cavagna","year":"2009","journal-title":"Jornal Brasileiro de Reproducao Assistida"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0032|cit32","unstructured":"Compare clinical outcome in conventional ART protocol and novel AMH tailored protocol in ART a prospective randomised controlled trial www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=4633"},{"issue":"5","key":"10.1002\/14651858.CD012693.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0015-0282(00)00414-3","article-title":"A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the \"follicle-stimulating hormone window\" combined with the gonadotropin-releasing hormone antagonist cetrorelix","volume":"73","author":"De Jong","year":"2000","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0034|cit34","first-page":"64","article-title":"The clinical efficacy of recombinant FSH (r-FSH) as compared to highly purified urinary gonadotrophin (hMG-FD) and the use of a low starting dose of r-FSH in IVF or ICSI. A randomized prospective study","volume":"14","author":"Drakakis","year":"2002","journal-title":"Italian Journal of Gynaecology & Obstetrics"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0035|cit35","first-page":"26","article-title":"A prospective randomized clinical trial of four fixed starting doses of recombinant FSH in women undergoing ovarian stimulation for IVF","volume":"15","author":"Fluker","year":"2000","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.12988","article-title":"Randomized controlled trial of gonadotropin- releasing hormone agonist microdose flare- up versus flare- up among poor responders undergoing intracytoplasmic sperm injection","volume":"148","author":"Ghaffari","year":"2020","journal-title":"International Journal of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0037|cit37","unstructured":"Individual versus standard follicle stimulating hormone dose for controlled ovarian stimulation and insemination clinicaltrials.gov\/study\/NCT00374634"},{"issue":"10","key":"10.1002\/14651858.CD012693.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1093\/humrep\/dep239","article-title":"Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study","volume":"24","author":"la Cour Freiesleben","year":"2009","journal-title":"Human Reproduction"},{"issue":"5","key":"10.1002\/14651858.CD012693.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0015-0282(01)02844-8","article-title":"A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization","volume":"76","author":"Latin-American Puregon IVF Study Group","year":"2001","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.rbmo.2021.10.020","article-title":"Reintroducing serum FSH measurement during ovarian stimulation for ART","volume":"44","author":"Lawrenz","year":"2022","journal-title":"Reproductive BioMedicine Online"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012693.pub3-BIB0041|cit41","first-page":"i106","article-title":"Gonadotropin endocytosis as a biomarker of optimal FSH dosage-a randomised clinical trial","volume":"32","author":"Lobato-Pascual","year":"2017","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0042|cit42","unstructured":"Luteal phase FSH in the IVF poor responder clinicaltrials.gov\/study\/NCT00225433"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0043|cit43","unstructured":"Comparison of ovarian mild stimulation and controlled ovarian stimulation in poor ovarian responders (POR) clinicaltrials.gov\/study\/NCT01926210"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0044|cit44","unstructured":"Effectiveness and safety study of fixed versus flexible of gonadotropin-releasing hormone antagonist protocol (GnRH) clinicaltrials.gov\/study\/NCT02635607"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0045|cit45","unstructured":"Optimising FSH dosage during in vitro fertilization (IVF) clinicaltrials.gov\/ct2\/show\/NCT02915900"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0046|cit46","unstructured":"The effectiveness and safety of the prolonged down-regulation protocol for controlled ovarian hyperstimulation ClinicalTrials.gov"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/humrep\/14.3.622","article-title":"A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation","volume":"14","author":"Out","year":"1999","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0048|cit48","first-page":"29","article-title":"Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation","volume":"15","author":"Out","journal-title":"2000"},{"issue":"6","key":"10.1002\/14651858.CD012693.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/humrep\/16.6.1104","article-title":"A randomized, double-blind clinical trial using fixed daily doses of 100 IU or 200 IU of recombinant FSH in ICSI cycles","volume":"16","author":"Out","year":"2001","journal-title":"Human Reproduction"},{"issue":"10","key":"10.1002\/14651858.CD012693.pub3-BIB0050|cit50","first-page":"1151","article-title":"Comparison of two different fixed doses of follitropin-\u03b2 in controlled ovarian hyperstimulation: a prospective randomized, double blind clinical trial","volume":"87","author":"Pruksananonda","year":"2004","journal-title":"Journal of the Medical Association of Thailand"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0051|cit51","unstructured":"Rasmussen BB Mannaerts B Klein BM Helmgaard L Arce JC ESTHER-1 trial group Low immunogenicity potential of follitropin delta, a recombinant FSH preparation produced from a human cell line: results from phase 3 trials (ESTHER-1 and ESTHER-2) Abstracts of the 32nd Annual Meeting of the European Society of Human Reproduction and Embryology 2016"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0052|cit52","first-page":"125","article-title":"A randomized study comparing Puregon 100 IU or 150 IU as starting dose in IVF treatment","volume":"Abstract book 1","author":"Simberg","year":"2000","journal-title":"Human Reproduction"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012693.pub3-BIB0053|cit53","first-page":"i1","article-title":"Fully human glycooptimized recombinant FSH: a randomized, assessor-blind, multi-center, multi-national phase II trial to investigate the efficacy and safety of FSH-GEX in women undergoing ART","volume":"29","author":"Tandler-Schneider","year":"2014","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/jhrs.JHRS_55_17","article-title":"Effectiveness of anti-mullerian hormone-tailored protocol compared to conventional protocol in women undergoing in vitro fertilization: a randomized controlled trial","volume":"11","author":"Thomas","year":"2018","journal-title":"Journal of Human Reproductive Sciences"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0055|cit55","unstructured":"Tsagareishvili G Khonelidze N Lazarev A Results of application of high daily doses of recombinant follicle stimulating hormone in different age groups of women in IVF program Georgian Medical News 2005 11"},{"issue":"8","key":"10.1002\/14651858.CD012693.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/humrep\/16.8.1676","article-title":"A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF\/ICSI","volume":"16","author":"Wikland","year":"2001","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0057|cit57","first-page":"112","article-title":"A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial","volume":"32","author":"Youssef","year":"2017","journal-title":"Human Reproduction"},{"issue":"4","key":"10.1002\/14651858.CD012693.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.rbmo.2018.12.032","article-title":"Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and\/or the need for additional preventive interventions: cumulative data over three stimulation cycles","volume":"38","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2019","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12958-023-01090-w","article-title":"Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol","volume":"21","author":"Fernandez Sanchez","year":"2023","journal-title":"Reproductive Biology and Endocrinology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012693.pub3-BIB0060|cit60","first-page":"i7","article-title":"The individualised dosing algorithm of follitropin delta, developed in a GnRH antagonist protocol, shows to be highly effective in a long GnRH agonist protocol","volume":"37","author":"Fernandez Sanchez","year":"2022","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Janse F Eijkemans M Fauser B Improved safety and efficiency of individualised versus conventional gonadotropin dosing for ovarian stimulation in IVF\/ICSI: an individual patient meta-analysis (IPD-MA) Human Reproduction 36 Suppl 1 https:\/\/doi.org\/10.1093\/humrep\/deab126.023","DOI":"10.1093\/humrep\/deab126.023"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12958-022-01016-y","article-title":"Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization\/intracytoplasmic sperm injection","volume":"20","author":"Yang","year":"2022","journal-title":"Reproductive Biology and Endocrinology"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0063|cit63","unstructured":"Phase III study to evaluate the efficacy and safety of recombinant human FSH of Cadila Healthcare Limited, India as compared to Gonal-F administered subcutaneously in female patients undergoing assisted reproductive technology ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=16431&EncHid=&userName=CTRI\/2016\/10\/007367"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0064|cit64","unstructured":"Efficacy and safety of FSH-GEX\u2122 in comparison with 150 IU Gonal-f\u00ae clinicaltrials.gov\/ct2\/show\/NCT01794208"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0065|cit65","unstructured":"Tailored ovarian stimulation based on BMI, AMH, AFC clinicaltrials.gov\/ct2\/show\/NCT02430740"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0066|cit66","unstructured":"Antimullerian hormone versus antral follicle count for determination of gonadotropin dosing in IVF clinicaltrials.gov\/ct2\/show\/NCT02739269"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0067|cit67","unstructured":"CLBR per initial cycle with different starting dose in aged patients with poor ovarian reservation: 300IU versus 150IU clinicaltrials.gov\/ct2\/show\/NCT03914651"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0068|cit68","unstructured":"Cumulative pregnancy rate with lower and higher gonadotropin dose during IVF among poor responders clinicaltrials.gov\/ct2\/show\/NCT05103228"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0069|cit69","first-page":"i419","article-title":"A prospective randomised controlled trial (RCT) on the role of AMH tailored stimulation protocols (Agonist or Antagonist), in improving IVF outcome in previous failed cycles","volume":"30","author":"Singh","year":"2015","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0070|cit70","unstructured":"Alam V Query on trial: CONSORT vs 150 for FSH dosing Email to: Lensen S"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/0974-1208.97795","article-title":"Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF\/ICSI program","volume":"5","author":"Aljawoan","year":"2012","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"12","key":"10.1002\/14651858.CD012693.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/humrep\/del284","article-title":"Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial","volume":"21","author":"Andersen","year":"2006","journal-title":"Human Reproduction"},{"issue":"6","key":"10.1002\/14651858.CD012693.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.fertnstert.2012.12.048","article-title":"Antim\u00fcllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients","volume":"99","author":"Arce","year":"2013","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","article-title":"Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"106","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2016","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0075|cit75","unstructured":"Bastu E Query on trial: 450 vs 300 IU FSH. Eur J Obstet Gynecol Reprod Biol 2016 Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0076|cit76","unstructured":"Berkkanoglu M Query on trial: 600 vs 450 vs 300 IU FSH. Fertility and sterility 2010 Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/humupd\/dmg045","article-title":"The endometrium in stimulated cycles for IVF","volume":"9","author":"Bourgain","year":"2003","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/humupd\/dml034","article-title":"A systematic review of tests predicting ovarian reserve and IVF outcome","volume":"12","author":"Broekmans","year":"2006","journal-title":"Human Reproduction Update"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.fertnstert.2009.04.040","article-title":"The antral follicle count: practical recommendations for better standardization","volume":"94","author":"Broekmans","year":"2010","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0080|cit80","unstructured":"Broekmans F Query on trial: Klinkert 2005 Email to: Lensen S"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.fertnstert.2013.04.024","article-title":"Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis","volume":"100","author":"Broer","year":"2013","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/humupd\/dms041","article-title":"Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach","volume":"19","author":"Broer","year":"2013","journal-title":"Human Reproduction Update"},{"issue":"5","key":"10.1002\/14651858.CD012693.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/humupd\/dmu020","article-title":"Anti-M\u00fcllerian hormone: ovarian reserve testing and its potential clinical implications","volume":"20","author":"Broer","year":"2014","journal-title":"Human Reproduction Update"},{"issue":"8","key":"10.1002\/14651858.CD012693.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/humrep\/dew151","article-title":"Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE","volume":"31","author":"Calhaz-Jorge","year":"2016","journal-title":"Human Reproduction"},{"issue":"7","key":"10.1002\/14651858.CD012693.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/humrep\/dew082","article-title":"International committee for monitoring assisted reproductive technologies world report: Assisted reproductive technology 2008, 2009 and 2010","volume":"31","author":"Dyer","year":"2016","journal-title":"Human Reproduction"},{"issue":"4","key":"10.1002\/14651858.CD012693.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.fertnstert.2017.08.016","article-title":"Patient-tailored ovarian stimulation for in vitro fertilization","volume":"108","author":"Fauser","year":"2017","journal-title":"Fertility and Sterility"},{"issue":"7","key":"10.1002\/14651858.CD012693.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria","volume":"26","author":"Ferraretti","year":"2011","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0088|cit88","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2014"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.fertnstert.2009.03.102","article-title":"Assisted reproductive technologies (ART) in Canada: 2006 results from the Canadian ART Register","volume":"93","author":"Gunby","year":"2010","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0090|cit90","unstructured":"Hamoda H Query on trial: individualised versus standard dosage of recombinant FSH Email to: Lensen S"},{"issue":"10","key":"10.1002\/14651858.CD012693.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/humrep\/deu218","article-title":"Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement","volume":"29","author":"Harbin Consensus Workshop Group","year":"2014","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0092|cit92","unstructured":"Harris K Fitzgerald O Paul RC Macaldowie A Lee E Chambers GM Assisted reproductive technology in Australia and New Zealand 2014 Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales, 2016"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0093|cit93","unstructured":"Helmgaard L Query on trial: Arce 2017 Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0094|cit94","unstructured":"Helmgaard L n\/a Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1002\/sim.3427","article-title":"Meta-analysis of skewed data: combining results reported on log-transformed or raw scales","volume":"27","author":"Higgins","year":"2008","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0097|cit97","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0098|cit98","unstructured":"Jayaprakasan K Query on trial: 225 v 300 IU FSH. 2010 Email to: Lensen S"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jama.2014.14488","article-title":"Safety of assisted reproductive technology in the United States, 2000-2011","volume":"313","author":"Kawwass","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0015-0282(02)03323-X","article-title":"Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up","volume":"78","author":"Kolibianakis","year":"2002","journal-title":"Fertility and Sterility"},{"issue":"10","key":"10.1002\/14651858.CD012693.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/humrep\/deu175","article-title":"European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE","volume":"29","author":"Kupka","year":"2014","journal-title":"Human Reproduction"},{"issue":"10","key":"10.1002\/14651858.CD012693.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1471-0528.2012.03412.x","article-title":"Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles","volume":"119","author":"La Marca","year":"2012","journal-title":"BJOG"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Human Reproduction Update"},{"issue":"5","key":"10.1002\/14651858.CD012693.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.fertnstert.2017.08.029","article-title":"Female age, serum antim\u00fcllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization\/intracytoplasmic sperm injection cycles","volume":"108","author":"La Marca","year":"2017","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0105|cit105","unstructured":"La Marca A Query on trial: Nomogram for FSH dosing 2017 Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0106|cit106","first-page":"5637923","article-title":"A higher ovarian response after stimulation for IVF is related to a higher number of euploid embryos","volume":"2017","author":"Labarta","year":"2017","journal-title":"BioMed Research International"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0107|cit107","unstructured":"Lan TN Query on trial: AMH vs AFC trial for FSH dosing Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0108|cit108","unstructured":"Lefebvre J Query on trial: 450 vs 600 IU FSH. Lefebvre 2015 Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0109|cit109","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"11-12","key":"10.1002\/14651858.CD012693.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10815-008-9266-6","article-title":"Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve","volume":"25","author":"Lekamge","year":"2008","journal-title":"Journal of Assisted Reproduction and Genetics"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"Magnusson A Query on trial: Use of AMH in an algorithm for IVF. HR 2017 Email to: Lensen S","DOI":"10.1093\/hropen\/hox026"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0093-691X(85)90181-5","article-title":"Superovulation of beef heifers with Pergonal (HMG): a dose response trial","volume":"24","author":"McGowan","year":"1985","journal-title":"Theriogenology"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O'Brien","year":"1979","journal-title":"Biometrics"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0114|cit114","unstructured":"Popovic-Todorovic B Query on trial 150 vs 100-250 FSH for IVF Email to: Lensen S"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1095\/biolreprod.104.032003","article-title":"Follicle-stimulating hormone affects metaphase I chromosome alignment and increases aneuploidy in mouse oocytes matured in vitro","volume":"72","author":"Roberts","year":"2005","journal-title":"Biology of Reproduction"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/hropen\/hox018","article-title":"How much variation in oocyte yield after controlled ovarian stimulation can be explained? A multilevel modelling study","volume":"2017","author":"Rustamov","year":"2017","journal-title":"Human Reproduction Open"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0015-0282(01)03201-0","article-title":"Early follicular serum m\u00fcllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles","volume":"77","author":"Seifer","year":"2002","journal-title":"Fertility and Sterility"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/humupd\/dmq041","article-title":"Clinical outcomes in relation to the daily dose of recombinant follicle stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis","volume":"17","author":"Sterrenburg","year":"2011","journal-title":"Human Reproduction Update"},{"issue":"4","key":"10.1002\/14651858.CD012693.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1292\/jvms.59.223","article-title":"Use of highly purified porcine FSH preparation for superovulation in Japanese black cattle","volume":"59","author":"Sugano","year":"1997","journal-title":"Journal of Veterinary Medical Science"},{"issue":"7","key":"10.1002\/14651858.CD012693.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Human Reproduction"},{"issue":"17","key":"10.1002\/14651858.CD012693.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1158\/1078-0432.CCR-12-3722","article-title":"Trial designs for personalizing cancer care: a systematic review and classification","volume":"19","author":"Tajik","year":"2013","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD012693.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.fertnstert.2012.11.037","article-title":"Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach","volume":"99","author":"Thoma","year":"2013","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0124|cit124","unstructured":"Thong KJ Query on trial: 150 v 225 IU FSH. Yong 2003 Email to: Lensen S"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.fertnstert.2009.07.054","article-title":"The influence of FSH on the aneuploidy rate of human in vitro matured oocytes","volume":"92","author":"Ting","year":"2009","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0126|cit126","first-page":"556","article-title":"Cumulative live birthrates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols","volume":"32","author":"Toftager","year":"2017","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0127|cit127","unstructured":"Torrance H Query on van Tilborg 2017 Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0128|cit128","unstructured":"Trew G Query on study: Out 2004 Email to: Lensen S"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/humrep\/deg133","article-title":"Common statistical errors in the design and analysis of subfertility trials","volume":"18","author":"Vail","year":"2003","journal-title":"Human Reproduction"},{"issue":"12","key":"10.1002\/14651858.CD012693.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1093\/humrep\/17.12.3065","article-title":"Serum anti-M\u00fcllerian hormone levels: a novel measure of ovarian reserve","volume":"17","author":"Van Rooij","year":"2002","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD012693.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/aogs.13032","article-title":"Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review","volume":"95","author":"Van Tilborg","year":"2016","journal-title":"Acta Obstetricia et Gynecologica Scandinavica"},{"issue":"1","key":"10.1002\/14651858.CD012693.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/rep.1.00529","article-title":"Anti-M\u00fcllerian hormone: a new marker for ovarian function","volume":"131","author":"Visser","year":"2006","journal-title":"Reproduction"},{"issue":"3","key":"10.1002\/14651858.CD012693.pub3-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011184.pub2","article-title":"Fresh versus frozen embryo transfers in assisted reproduction","author":"Wong","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD012693.pub3-BIB0134|cit134","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001302","article-title":"Volume expanders for the prevention of ovarian hyperstimulation syndrome","author":"Youssef","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012693.pub3-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012693","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing IVF\/ICSI","author":"Lensen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012693.pub3-BIB0136|cit136","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012693.pub2","article-title":"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF\/ICSI)","author":"Lensen","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T10:19:40Z","timestamp":1735208380000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012693.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecology and Fertility Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012693.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}